Suggested remit: To appraise the clinical and cost effectiveness of nivolumab with ipilumumab and standard chemotherapy (platinum-based combination chemotherapy) within its marketing authorisation for untreated metastatic non-small-cell lung cancer.
Status In progress
Process STA 2018
ID number 1566

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics, University of York


Key events during the development of the guidance:

Date Update
06 April 2020 - 07 May 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
01 April 2019 In progress. Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance